WMSA
GRCE

Weiss Multi-Strategy Advisers’s Grace Therapeutics GRCE Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,042
Closed -$95K – 751
2019
Q3 		$95K Buy
+1,042
New +$96.5K ﹤0.01% 557

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PP
Peconic Partners New York $5.78B AUM 127.23% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Weiss Multi-Strategy Advisers's GRCE Position: Q4 2019 in Review

Weiss Multi-Strategy Advisers sold out of Grace Therapeutics (GRCE) in Q4 2019, closing a stake of 1,042 shares — an estimated $95K sold.

Weiss Multi-Strategy Advisers first reported a position in GRCE in Q3 2019 and held it in 1 quarter. The position peaked at $95K in Q3 2019. 33 funds tracked by Wall St. Rank hold GRCE as of Q4 2019.

  • Weiss Multi-Strategy Advisers reported no remaining Grace Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 1,042 Grace Therapeutics shares in Q4 2019, an estimated $95K.
  • Weiss Multi-Strategy Advisers first reported a position in Grace Therapeutics in Q3 2019 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Grace Therapeutics position peaked at $95K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2019.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2019, filed 14 Feb 2020.